The report, which provides an update on all the monumental changes witnessed by the field of oncology over the last year, highlights 3 key achievements: new investments in science and insurance coverage, payment models that emphasize quality, and rapid-learning healthcare systems.
Do newer forms of radiation treatments surpass standard radiation in prostate cancer?
A preview of some of the discussions at the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN).
The White House budget “blueprint” for 2018, which was released today, has recommended substantial cuts to the National Institutes of Health (NIH).
Ken Tarkoff, formerly at RelayHealth, is joining Syapse as its new CEO.
New research published in Nature Medicine has identified a broader population of individuals with breast cancer who can have therapeutic sensitivity to PARP inhibitors.
A new study, published in the Journal of the National Cancer Institute, has confirmed that mammographic density change following estrogen and progestin treatment increases the risk of breast cancer.
The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.
A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious.
A new study from the MD Anderson Cancer Center has identified factors that influence cancer clinical trial accrual rates.
Several medical interest groups have raised their opposition to the new Republican plan drafted to replace the Affordable Care Act.
A pilot study conducted at a safety net hospital has armed researchers with a new educational tool: a digital app to persuade parents to vaccinate their adolescent against the human papilloma virus (HPV).
Pharmacists and pharmacy technicians working at 50 specialty pharmacy locations owned by Walgreens have completed a cancer-focused curriculum of advanced education courses.
How will drug developers price gene therapy treatments to recover their investment and ensure that society can bear the impending cost?
Implementation of clinical pathways saved $15,013 in the total cost of care per patient over a year.
The roundtable provides a forum for academic researchers, health policy experts, patient advocates, health insurance plans, and the pharmaceutical industry to debate on the most sustainable strategies for patient cost sharing for medications.
While colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining.
The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.
A key takeaway from a panel discussion at the Patient Access Network Foundation’s second cost-sharing roundtable was the need for educating stakeholders.
Expanding a health system pharmacy’s operations to include specialty drugs, namely oral oncology agents, improved patient care by reducing errors and saving costs.
A new grant aims to gather data on thousands of African American cancer survivors to understand factors that influence disease progression, recurrence, mortality, and quality of life.
At the 2nd cost-sharing roundtable hosted by the Patient Access Network Foundation and The American Journal of Managed Care®, Tricia Neuman of the Kaiser Family Foundation provided a perspective on what the future might hold for patients enrolled in Medicare.
Using body composition metrics to guide the dose in patients receiving anthracyclines-taxane—based chemotherapy for breast cancer can reduce treatment-related toxicity.
Amgen and Harvard Pilgrim Healthcare have entered an outcomes-based contract that is based on the efficacy of Amgen’s immunomodulatory agent etanercept (Enbrel), for patients with rheumatoid arthritis.
As payment models shift to emphasize patient experience and quality of care, a panel discussion at the 5th annual Patient-Centered Oncology Care® meeting debated whether these efforts had meaningfully improved outcomes for patients.
The company's study has found a 38% drop in cigarette purchase among shoppers who visit CVS stores.
Specialty pharmacies can collaborate with clinical teams to harness the power of health information technology and improve cancer care, according to panelists at the 5th annual Patient-Centered Oncology Care® meeting.
Including anti-cholesterol agents during adjuvant endocrine treatment can prevent breast cancer recurrence in hormone receptor—positive early-stage breast cancer.
David L. Porter, MD, kicked off the 5th annual Patient-Centered Oncology Care® (PCOC®) meeting in Baltimore on November 17, 2016, with an update on chimeric antigen receptor T-cell therapy.
At the 5th annual Patient-Centered Oncology Care® meeting, hosted by The American Journal of Managed Care®, experts discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.